Biopharmaceutical company, Third Harmonic Bio, Inc. (THRD), Thursday appointed Christopher Murphy as Chief Financial and Business Officer. Also, the company announced business updates regarding its program THB335.
In October, the company had announced the resignation of the then finance chief Robert Ho effective November 10, 2023.
Previously, Murphy served as a member of leadership team of Horizon Therapeutics PLC, where he helped to increase the profitability of the company. Under his leadership, Horizon was later acquired by Amgen Inc. for $28 billion in October 2023.
Further, the company plans to file a U.S. IND and initiate a Phase 1 SAD/14-day MAD study of its lead program THB335 in the first half of 2024, the company said in a statement.
In the pre-market activity, Third Harmonic's stock stands at $10.68 without any movement on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.